Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2007
At a glance
- Drugs CAT 3888 (Primary)
- Indications Burkitt's lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 21 Dec 2007 Status change from recruiting to suspended.
- 06 Sep 2005 New trial record.